GlassScriptPhysician profile
Joseph C Duflot
NPI 1467420679
$5,084.43
in general payments reported to CMS, 2019-2025
30 companies · $889 in 2025
The $889 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $807 · 2020: $390 · 2021: $156 · 2022: $837 · 2023: $861 · 2024: $1,145 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,881 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,880.79 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $942.64 | 2019-2025 | Krystexxa, Tavneos, Aranesp |
| Otsuka America Pharmaceutical, INC. | $564.12 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $476.24 | 2019-2025 | Farxiga, Lokelma |
| Octapharma USA, INC. | $380.48 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $298.62 | 2022-2025 | Acthar |
| Horizon Therapeutics Plc | $278.45 | 2021-2023 | Krystexxa |
| Travere Therapeutics, INC. | $253.09 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $220.32 | 2019-2023 | Velphoro |
| Glaxosmithkline, LLC. | $185.34 | 2021-2024 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $176.69 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $152.06 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.86 | 2022-2024 | Jardiance |
| Baxter Healthcare | $124.74 | 2019 | |
| Akebia Therapeutics INC | $122.57 | 2020-2025 | Vafseo |
| Calliditas Therapeutics US INC. | $118.55 | 2022-2025 | Tarpeyo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $91.82 | 2019-2025 | Veltassa |
| Genzyme Corporation | $86.12 | 2023-2024 | |
| Aurinia Pharma U.S., INC. | $83.43 | 2022-2024 | Lupkynis |
| Lilly USA, LLC | $64.07 | 2024-2025 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $59.04 | 2019-2022 | |
| Kyowa Kirin, INC. | $48.87 | 2024-2025 | Crysvita |
| Alexion Pharmaceuticals, INC. | $39.76 | 2019-2020 | |
| Amicus Therapeutics, INC. | $36.09 | 2019-2023 | Galafold |
| Shield Therapeutics INC | $27.82 | 2025 | |
| Shire North American Group INC | $24.74 | 2019 | |
| Nxstage Medical, INC. | $19.91 | 2025 | Nxstage System One |
| Ani Pharmaceuticals, INC. | $19.80 | 2024 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $17.75 | 2024 | |
| Mallinckrodt Enterprises LLC | $15.75 | 2019 | |
| Genentech USA, INC. | $15.69 | 2025 | Gazyva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Duflot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.